机器学习在急性髓系白血病管理中的应用:现状与前景
本文综述机器学习在急性髓系白血病(AML)管理中的应用进展。ML算法可处理大量医学数据,整合不同诊断模态信息预测预后并建议治疗策略,有望实现快速准确诊断、精准风险分层和优化治疗。但技术存在缺陷,需严格监管框架确保安全使用。
要点
- ML可整合多模态诊断数据,辅助AML快速诊断与精准风险分层。
- ML在AML预后预测和治疗策略建议方面展现应用潜力。
- ML临床转化需警惕技术缺陷并建立严格监管框架。
核心结论
- ML是未来血液系统恶性肿瘤管理的有前景工具,AML是近期多项研究的模型疾病。
研究设计与样本
- 本文为综合性综述,聚焦ML技术在AML管理中的最新进展。
主要发现
- ML算法能处理大量医学数据并增进对恶性疾病的理解。
- ML可处理不同诊断模态的信息,预测预后并建议治疗策略。
- 将ML技术整合至AML管理各环节可实现快速准确诊断、精准风险分层和优化治疗。
临床怎么用
- ML技术有望融入AML管理流程,辅助诊断、风险分层和治疗决策。
- 临床应用ML需认识其技术缺陷并遵循严格监管框架以确保安全。
局限性
- ML技术存在多种缺陷,需严格监管框架保障安全使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Machine learning (ML) is rapidly emerging in several fields of cancer research. ML algorithms can deal with vast amounts of medical data and provide a better understanding of malignant disease. Its ability to process information from different diagnostic modalities and functions to predict prognosis and suggest therapeutic strategies indicates that ML is a promising tool for the future management of hematologic malignancies; acute myeloid leukemia (AML) is a model disease of various recent studies. An integration of these ML techniques into various applications in AML management can assure fast and accurate diagnosis as well as precise risk stratification and optimal therapy. Nevertheless, these techniques come with various pitfalls and need a strict regulatory framework to ensure safe use of ML. This comprehensive review highlights and discusses recent advances in ML techniques in the management of AML as a model disease of hematologic neoplasms, enabling researchers and clinicians alike to critically evaluate this upcoming, potentially practice-changing technology.
引用
- Eckardt JN, Bornhäuser M, Wendt K, et al. Application of machine learning in the management of acute myeloid leukemia: current practice and future prospects. Blood Adv. 2020. PMID: 33290546. doi:10.1182/bloodadvances.2020002997
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。